Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Policy had been used to limit expenditures for prostate cancer drugs and inhaled drugs for pulmonary disease.